Purification, Characterization, and Structural Elucidation of Serralysin-Like Alkaline Metalloprotease from a Novel Source
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Biochemical Characterization of Human Matrix Metalloproteinases and Their Newly Designed Inhibitors Related to Stroke Qiang Cao
Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2010 Biochemical Characterization of Human Matrix Metalloproteinases and Their Newly Designed Inhibitors Related to Stroke Qiang Cao Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] THE FLORIDA STATE UNIVERSITY COLLEGE OF ARTS AND SCIENCES BIOCHEMICAL CHARACTERIZATION OF HUMAN MATRIX METALLOPROTEINASES AND THEIR NEWLY DESIGNED INHIBITORS RELATED TO STROKE By QIANG CAO A Dissertation submitted to the Department of Chemistry and Biochemistry in partial fulfillment of the requirements for the degree of Doctor of Philosophy Degree Awarded: Fall Semester, 2010 The members of the committee approve the dissertation of Qiang Cao defended on July 14, 2010. Qing-Xiang Amy Sang Professor Directing Dissertation Yan-Chang Wang University Representative Hong Li Committee Member Igor Alabugin Committee Member Approved: Joseph B. Schlenoff, Chair, Department of Chemistry and Biochemistry The Graduate School has verified and approved the above-named committee members. ii This dissertation is dedicated to my parents, Shi-De Cao & Mu-Dan Li. iii ACKNOWLEDGEMENTS There are many people to thank for their support and guidance during the past years. My wife, Juan Zhou, has shown a great deal of patience and personal support through difficult times. Professor Qing-Xiang Amy Sang has provided outstanding scientific guidance and truly developed my interest in cancer research and cardiovascular disease research. A special thanks is given to Drs. Martin Schwartz, Yonghao Jin and Wei Yang for the many discussions about inhibitor interactions the synthesis and modeling of the compounds. I especially thank Mark Dru Roycik for his help on English writing and organizing through the past years and Douglas R. -
Role of Extracellular Proteases in Biofilm Disruption of Gram Positive
e Engine ym er z in n g E Mukherji, et al., Enz Eng 2015, 4:1 Enzyme Engineering DOI: 10.4172/2329-6674.1000126 ISSN: 2329-6674 Review Article Open Access Role of Extracellular Proteases in Biofilm Disruption of Gram Positive Bacteria with Special Emphasis on Staphylococcus aureus Biofilms Mukherji R, Patil A and Prabhune A* Division of Biochemical Sciences, CSIR-National Chemical Laboratory, Pune, India *Corresponding author: Asmita Prabhune, Division of Biochemical Sciences, CSIR-National Chemical Laboratory, Pune 411008, India, Tel: 91-020-25902239; Fax: 91-020-25902648; E-mail: [email protected] Rec date: December 28, 2014, Acc date: January 12, 2015, Pub date: January 15, 2015 Copyright: © 2015 Mukherji R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Bacterial biofilms are multicellular structures akin to citadels which have individual bacterial cells embedded within a matrix of a self-synthesized polymeric or proteinaceous material. Since biofilms can establish themselves on both biotic and abiotic surfaces and that bacteria residing in these complex molecular structures are much more resistant to antimicrobial agents than their planktonic equivalents, makes these entities a medical and economic nuisance. Of late, several strategies have been investigated that intend to provide a sustainable solution to treat this problem. More recently role of extracellular proteases in disruption of already established bacterial biofilms and in prevention of biofilm formation itself has been demonstrated. The present review aims to collectively highlight the role of bacterial extracellular proteases in biofilm disruption of Gram positive bacteria. -
Serine Proteases with Altered Sensitivity to Activity-Modulating
(19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants. -
Therapeutic Effects of a Combined Antibiotic-Enzyme Treatment on Subclinical Mastitis in Lactating Dairy Cows
Veterinarni Medicina, 61, 2016 (5): 237–242 Original Paper doi: 10.17221/8876-VETMED Therapeutic effects of a combined antibiotic-enzyme treatment on subclinical mastitis in lactating dairy cows B. Khoramian1, M. Emaneini2, M. Bolourchi3, A. Niasari-Naslaji3, A. Gorganzadeh1, S. Abani1, P. Hovareshti3 1Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran 2School of Medicine, Tehran University of Medical Sciences. Tehran, Iran 3Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran ABSTRACT: The objective of this study was to evaluate a combined antibiotic-enzyme therapy for Staphylococcus aureus mastitis and biofilm formation. A total of 141 cases of S. aureus chronic mastitis from three farms were divided ® into two groups: the control group (n = 54) were treated with Nafpenzal ointment; the enzyme + antibiotic group ® ® (n = 87) were treated with Nafpenzal plus an enzymatic ointment (MastiVeyxym ). Quantitative determination of biofilm formation was determined using a colorimetric microplate assay and the detection of ica genes by PCR. Enzyme + antibiotic therapy did not significantly improve cure rates compared to control (48.3 vs 38.9%). The cure rate for infections caused by biofilm-positive strains was 42.6 and 46.6% for control and enzyme + antibiotic groups, respectively (P > 0.05). Comparison of cure rates between farms showed a relationship with somatic cell count (SCC), parity and oxacillin resistance. 79.4% of the isolates produced biofilm and antibacterial resistance rates for oxacillin, penicillin and streptomycin were 25.5, 71.6 and 95.7%, respectively. These results indicate that while the increase in mastitis cure rate using enzymatic therapy was not significant, this treatment could be useful in some situations. -
The Role of Serratiopeptidase in the Resolution of Inflammation
ARTICLE IN PRESS asian journal of pharmaceutical sciences ■■ (2017) ■■– ■■ Available online at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/ajps Review The role of serratiopeptidase in the resolution of inflammation Manju Tiwari * Department of Biochemistry and Genetics, Barkatullah University, Bhopal, Madhya Pradesh, India ARTICLE INFO ABSTRACT Article history: Inflammation remains a key event during most of the diseases and physiological imbal- Received 26 October 2016 ance. Acute inflammation is an essential physiological event by immune system for a protective Received in revised form 9 measure to remove cause of inflammation and failure of resolution lead to chronic inflam- December 2016 mation. Over a period of time, a number of drugs mostly chemical have been deployed to Accepted 16 January 2017 combat acute and chronic inflammation. Recently, enzyme based anti-inflammatory drugs Available online became popular over conventional chemical based drugs. Serratiopeptidase, a proteolytic enzyme from trypsin family, possesses tremendous scope in combating inflammation. Serine Keywords: protease possesses a higher affinity for cyclooxygenase (COX-I and COX-II), a key enzyme Inflammation associated with production of different inflammatory mediators including interleukins (IL), Cyclooxygenase prostaglandins (PGs) and thromboxane (TXs) etc. Currently, arthritis, sinusitis, bronchitis, NSAIDs fibrocystic breast disease, and carpal tunnel syndrome, etc. are the leading inflammatory Serratiopeptidase disorders that affected the entire the globe. In order to conquer inflammation, both acute Steroids and chronic world, physician mostly relies on conventional drugs. The most common drugs Enzyme therapeutics to combat acute inflammation are Nonsteroidal anti-inflammatory drugs (NSAIDs) alone and or in combination with other drugs. However, during chronic inflammation, NSAIDs are often used with steroidal drugs such as autoimmune disorders. -
Targeting Microbial Biofilms Using Ficin, a Nonspecific Plant Protease Diana R
www.nature.com/scientificreports OPEN Targeting microbial biofilms using Ficin, a nonspecific plant protease Diana R. Baidamshina1,*, Elena Y. Trizna1,*, Marina G. Holyavka2, Mikhail I. Bogachev3, Valeriy G. Artyukhov2, Farida S. Akhatova1, Elvira V. Rozhina1, Rawil F. Fakhrullin1 & 1 Received: 26 September 2016 Airat R. Kayumov Accepted: 08 March 2017 Biofilms, the communities of surface-attached bacteria embedded into extracellular matrix, are Published: 07 April 2017 ubiquitous microbial consortia securing the effective resistance of constituent cells to environmental impacts and host immune responses. Biofilm-embedded bacteria are generally inaccessible for antimicrobials, therefore the disruption of biofilm matrix is the potent approach to eradicate microbial biofilms. We demonstrate here the destruction ofStaphylococcus aureus and Staphylococcus epidermidis biofilms with Ficin, a nonspecific plant protease. The biofilm thickness decreased two-fold after 24hours treatment with Ficin at 10 μg/ml and six-fold at 1000 μg/ml concentration. We confirmed the successful destruction of biofilm structures and the significant decrease of non-specific bacterial adhesion to the surfaces after Ficin treatment using confocal laser scanning and atomic force microscopy. Importantly, Ficin treatment enhanced the effects of antibiotics on biofilms-embedded cells via disruption of biofilm matrices. Pre-treatment with Ficin (1000 μg/ml) considerably reduced the concentrations of ciprofloxacin and bezalkonium chloride required to suppress the viable Staphylococci by 3 orders of magnitude. We also demonstrated that Ficin is not cytotoxic towards human breast adenocarcinoma cells (MCF7) and dog adipose derived stem cells. Overall, Ficin is a potent tool for staphylococcal biofilm treatment and fabrication of novel antimicrobial therapeutics for medical and veterinary applications. -
Transcription Factor Eepr Is Required for Serratia Marcescens Host Proinflammatory Response by Corneal Epithelial Cells
antibiotics Article Transcription Factor EepR Is Required for Serratia marcescens Host Proinflammatory Response by Corneal Epithelial Cells Kimberly M. Brothers , Stephen A. K. Harvey and Robert M. Q. Shanks * Charles T. Campbell Ophthalmic Microbiology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; [email protected] (K.M.B.); [email protected] (S.A.K.H.) * Correspondence: [email protected]; Tel.: +1-412-647-3537 Abstract: Relatively little is known about how the corneal epithelium responds to vision-threatening bacteria from the Enterobacterales order. This study investigates the impact of Serratia marcescens on corneal epithelial cell host responses. We also investigate the role of a bacterial transcription factor EepR, which is a positive regulator of S. marcescens secretion of cytotoxic proteases and a hemolytic surfactant. We treated transcriptomic and metabolomic analysis of human corneal limbal epithelial cells with wild-type bacterial secretomes. Our results show increased expression of proinflammatory and lipid signaling molecules, while this is greatly altered in eepR mutant-treated corneal cells. Together, these data support the model that the S. marcescens transcription factor EepR is a key regulator of host-pathogen interactions, and is necessary to induce proinflammatory chemokines, cytokines, and lipids. Keywords: bacterial infection; Serratia marcescens; transcription factor; keratitis; ocular surface; epithelium; cornea; metabolomics Citation: Brothers, K.M.; Harvey, S.A.K.; Shanks, R.M.Q. Transcription Factor EepR Is Required for Serratia marcescens Host Proinflammatory 1. Introduction Response by Corneal Epithelial Cells. The cornea, the transparent, anterior layer of the eye, is essential for vision and pro- Antibiotics 10 2021, , 770. -
Role of Systemic Enzymes in Infections
Article ID: WMC002495 2046-1690 Role of Systemic Enzymes in Infections Corresponding Author: Dr. Sukhbir Shahid, Consultant Pediatrician, Pediatrics - India Submitting Author: Dr. Sukhbir Shahid, Consultant Pediatrician, Pediatrics - India Article ID: WMC002495 Article Type: Review articles Submitted on:22-Nov-2011, 08:16:56 AM GMT Published on: 22-Nov-2011, 02:34:00 PM GMT Article URL: http://www.webmedcentral.com/article_view/2495 Subject Categories:COMPLEMENTARY MEDICINE Keywords:Enzymes, Systemic enzymes, Infections, Sepsis, Proteolytic, Supplementary How to cite the article:Shahid S . Role of Systemic Enzymes in Infections . WebmedCentral COMPLEMENTARY MEDICINE 2011;2(11):WMC002495 Source(s) of Funding: None Competing Interests: None WebmedCentral > Review articles Page 1 of 13 WMC002495 Downloaded from http://www.webmedcentral.com on 23-Dec-2011, 07:57:46 AM Role of Systemic Enzymes in Infections Author(s): Shahid S Abstract infections[4]. The ‘battle’ between the host’s immunity and organism leads to a lot of ‘molecular’morbidity and mortality. Anti-infective agents do help but at times benefit is marginal. These agents may sometimes Enzymes are complex macromolecules of amino-acids worsen the situation through release of immune which bio-catalyse various body processes. Adequate complexes and dead bacilli into the blood stream. concentrations of enzymes are essential for optimal They also fail to reverse the hemodynamic instability functioning of the immune system. During infections, and immune paralysis characteristic of these body’s enzymatic system is attacked and hence the infections[4]. Supplementation with drugs targeted immune system is also likely to derange. This may be against this ‘choatic’ or ‘dysfunctional’ immune detrimental for the host’s well-being and existence. -
Functional and Structural Insights Into Astacin Metallopeptidases
Biol. Chem., Vol. 393, pp. 1027–1041, October 2012 • Copyright © by Walter de Gruyter • Berlin • Boston. DOI 10.1515/hsz-2012-0149 Review Functional and structural insights into astacin metallopeptidases F. Xavier Gomis-R ü th 1, *, Sergio Trillo-Muyo 1 Keywords: bone morphogenetic protein; catalytic domain; and Walter St ö cker 2, * meprin; metzincin; tolloid; zinc metallopeptidase. 1 Proteolysis Lab , Molecular Biology Institute of Barcelona, CSIC, Barcelona Science Park, Helix Building, c/Baldiri Reixac, 15-21, E-08028 Barcelona , Spain Introduction: a short historical background 2 Institute of Zoology , Cell and Matrix Biology, Johannes Gutenberg University, Johannes-von-M ü ller-Weg 6, The fi rst report on the digestive protease astacin from the D-55128 Mainz , Germany European freshwater crayfi sh, Astacus astacus L. – then termed ‘ crayfi sh small-molecule protease ’ or ‘ Astacus pro- * Corresponding authors tease ’ – dates back to the late 1960s (Sonneborn et al. , 1969 ). e-mail: [email protected]; [email protected] Protein sequencing by Zwilling and co-workers in the 1980s did not reveal homology to any other protein (Titani et al. , Abstract 1987 ). Shortly after, the enzyme was identifi ed as a zinc met- allopeptidase (St ö cker et al., 1988 ), and other family mem- The astacins are a family of multi-domain metallopepti- bers emerged. The fi rst of these was bone morphogenetic β dases with manifold functions in metabolism. They are protein 1 (BMP1), a protease co-purifi ed with TGF -like either secreted or membrane-anchored and are regulated growth factors termed bone morphogenetic proteins due by being synthesized as inactive zymogens and also by co- to their capacity to induce ectopic bone formation in mice localizing protein inhibitors. -
Book of Abstracts 2021
BOOK OF ABSTRACTS Preface Organisation Research in Groningen Congress Abstracts Plenary Abstracts Oral Abstracts Poster Postscript 2 Table of Contents Preface � � � � � � � � � � � � � � � � � � � � � � � � � � � 5 Cell Biology � � � � � � � � � � � � � � � � � � � � � � � 99 Tessa de Bruin � � � � � � � � � � � � � � � � � � � � � � 6 Endocrinology & Diabetes � � � � � � � � � � � � � �106 Prof� Marian Joëls MD PhD � � � � � � � � � � � � � � � 7 Pediatrics, Obstetrics & Reproductive health � �110 Organisation � � � � � � � � � � � � � � � � � � � � � � � 8 Neurology & Neurosurgery � � � � � � � � � � � � �115 Executive Board � � � � � � � � � � � � � � � � � � � � � 9 Cardiology & Vascular medicine � � � � � � � � � �122 Advisory Board � � � � � � � � � � � � � � � � � � � � � 10 Oncology I � � � � � � � � � � � � � � � � � � � � � � � �128 President, Secretary, Treasurer � � � � � � � � � � � 11 Pulmonology � � � � � � � � � � � � � � � � � � � � � �134 Scientific Programme � � � � � � � � � � � � � � � � � 12 Oral Sessions II � � � � � � � � � � � � � � � � � � � � 139 Sponsors & Fundraising � � � � � � � � � � � � � � � 13 Public health II � � � � � � � � � � � � � � � � � � � � �140 International Contacts � � � � � � � � � � � � � � � � 14 Oncology II � � � � � � � � � � � � � � � � � � � � � � �146 Hosting & Logistics � � � � � � � � � � � � � � � � � � 15 Epidemiology � � � � � � � � � � � � � � � � � � � � � �153 Public Relations � � � � � � � � � � � � � � � � � � � � 16 Pharmacology � � � � � � � � � � � � � � � � � � � � �160 -
Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48 -
Cimetidine for Use in Individuals With
Treatments for Painful and Other Fatty lumps (Lipomatosis): www.lipomadoc.org Karen L. Herbst, Ph.D. M.D. Updated:6/19/2008 Dercum’s disease or adiposis dolorosa (AD) is thought to be a rare disorder whose hallmark is multiple fatty growths1 which I will call lipomatosis as the growths tend to be multiple and can be spread over large areas. The lipomatosis is generally as unencapsulated lipomas, fibrolipomas or angiolipomas. In AD, the lipomatosis is painful to touch likely because of an alteration in the nerves in the underlying fat and its associated fascia or connective tissue. The fascia appears to be increased in and around the lipomatosis of AD perhaps participating in the stimulation and growth of the adipose (fat) cells within the lipomas. Inflammatory cells including lymphocytes, macrophages and eosinophils secrete factors causing necrosis and damage of tissue resulting in pain, and participate in the growth process by secreting growth factors; the actual stimulus for the fascia or adipose tissue growth is not known. These changes in the AD tissue suggest a problem with the immune system. There are no proven treatments for AD to date. In this monograph, you will find recommendations that may or may not help you. Until proven, these recommendations are for you and your doctor to think about and make choices based on your disease, medical history and overall current situation. I recommend the following for the treatment of AD: Recommendation I: Diet We have no idea at this time what causes the lipomatosis – is it metabolic, meaning that there is some pathway that is some metabolic pathway that is altered in AD? Is it genetic? Autoimmune ? Infectious? We do know fat is increased.